Sandbox g55: Difference between revisions

Jump to navigation Jump to search
mNo edit summary
mNo edit summary
Line 9: Line 9:
::::* 1.2.1 '''Susceptible to all tested drugs'''
::::* 1.2.1 '''Susceptible to all tested drugs'''
:::::* Preferred regimen: [[Piperacillin-Tazobactam]] 3.375 mg IV q6h
:::::* Preferred regimen: [[Piperacillin-Tazobactam]] 3.375 mg IV q6h
:::::* Alternative regimen (1): [[Ciprofloxacin]] 400 mg IV q12h or Cefepime 2 gm IV q8h
:::::* Alternative regimen (1): [[Ciprofloxacin]] 400 mg IV q12h
:::::* Alternative regimen (2): [[Cefepime]] 2 gm IV q8h
:::::* Alternative regimen (2): [[Cefepime]] 2 gm IV q8h



Revision as of 03:28, 22 July 2015

  • Enterobacter species including E. aerogenes and E. cloacae
  • 1. Non–life-threatening infections or MDR-GNB prevalence < 20%
  • 1.1 Empiric antimicrobial therapy pending in vitro susceptibility
  • 1.2 In vitro susceptibility available
  • 1.2.1 Susceptible to all tested drugs





  • Acanthamoeba species



  • Balamuthia mandrillaris



References